These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
62 related articles for article (PubMed ID: 7813597)
41. Can insulin-dependent diabetes mellitus be cured or prevented? A status report on immunomodulatory strategies and pancreas transplantation. Drash AL; Arslanian SA Pediatr Clin North Am; 1990 Dec; 37(6):1467-87. PubMed ID: 2259549 [TBL] [Abstract][Full Text] [Related]
43. Reversal of type 1 diabetes in mice. Faustman DL N Engl J Med; 2007 Jan; 356(3):311-2. PubMed ID: 17229964 [No Abstract] [Full Text] [Related]
44. Type 1 diabetes mellitus in 2011: Heterogeneity of T1DM raises questions for therapy. Pozzilli P Nat Rev Endocrinol; 2011 Dec; 8(2):78-80. PubMed ID: 22183128 [TBL] [Abstract][Full Text] [Related]
45. Immunotherapy of type I diabetes. Kolb H; Greulich B; Kiessel U; Gries FA Lancet; 1982 Jul; 2(8289):97-8. PubMed ID: 6123832 [No Abstract] [Full Text] [Related]
46. Immunotherapy of immune-mediated diabetes. Present and future. Maclaren N Clin Rev Allergy Immunol; 2000 Dec; 19(3):277-97. PubMed ID: 11138410 [No Abstract] [Full Text] [Related]
47. Immune intervention yes, but for what reason, for whom, when and how? Lernmark A Diabetologia; 1992 Nov; 35(11):1096-8. PubMed ID: 1473622 [No Abstract] [Full Text] [Related]
48. The SAgA of Antigen-Specific Immunotherapy for Type 1 Diabetes. Mallone R; You S Diabetes; 2021 Jun; 70(6):1247-1249. PubMed ID: 34016601 [No Abstract] [Full Text] [Related]
49. A machine learning approach to predict response to immunotherapy in type 1 diabetes. Fousteri G; Rodrigues EM; Giamporcaro GM; Falcone M Cell Mol Immunol; 2021 Mar; 18(3):515-517. PubMed ID: 33318626 [No Abstract] [Full Text] [Related]
50. Prologue. Diabetes. An old disease, a new insight. Ahmad SI Adv Exp Med Biol; 2012; 771():xxvii-xxxiii. PubMed ID: 23393664 [No Abstract] [Full Text] [Related]
51. [Immunotherapy of type 1 diabetes mellitus: current state-of-the-art and prospects. Part 2]. Laptev DN Probl Endokrinol (Mosk); 2009 Oct; 55(5):31-38. PubMed ID: 31569853 [TBL] [Abstract][Full Text] [Related]
54. Prediabetes in children: natural history, diagnosis, and preventive strategies. Kulmala P Paediatr Drugs; 2003; 5(4):211-21. PubMed ID: 12662117 [TBL] [Abstract][Full Text] [Related]
55. An islet-cell protein tyrosine phosphatase is a likely precursor to the 37-kDa autoantigen in type 1 diabetes: human and macaque sequences, tissue distribution, unique and shared epitopes, and predictive autoantibodies. LaGasse J; Jelinek L; Sexson S; Lofton-Day C; Breininger J; Sheppard P; Kindsvogel W; Hagopian WA Mol Med; 1997 Mar; 3(3):163-73. PubMed ID: 9100223 [TBL] [Abstract][Full Text] [Related]
56. Immune intervention in type I diabetes mellitus--current clinical and experimental approaches. Kolb H Exp Clin Endocrinol; 1994; 102(4):269-72. PubMed ID: 7813597 [TBL] [Abstract][Full Text] [Related]
57. [Immunoprevention of Type I diabetes mellitus]. Spinas GA Ther Umsch; 1996 Dec; 53(12):882-8. PubMed ID: 9036566 [TBL] [Abstract][Full Text] [Related]
58. [Principles of immunotherapy in insulin-dependent diabetes mellitus]. Bretzel RG Wien Klin Wochenschr; 1988 Jun; 100(13):435-42. PubMed ID: 3043913 [TBL] [Abstract][Full Text] [Related]
59. New prospects for immunotherapy at diagnosis of type 1 diabetes. Pozzilli P; Leslie RD Diabetes Metab Res Rev; 2009 May; 25(4):299-301. PubMed ID: 19405079 [TBL] [Abstract][Full Text] [Related]
60. Genes and engineered cells as drugs for type I and type II diabetes mellitus therapy and prevention. Giannoukakis N; Pietropaolo M; Trucco M Curr Opin Investig Drugs; 2002 May; 3(5):735-51. PubMed ID: 12090547 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]